CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. As a new treatment met…